Loading…
Cadrenal Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CVKD.
▼ -97.2% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $6.78 | $14.49 | $11.10 | |
| P/B | 3.7x | 6.2x | 3.7x | 1.5x |
| EPS | -$6.64 | -$8.73 | -$9.29 | |
| ROE | -143.17% | -483.34% | -143.17% | -108.64% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| JUNSJupiter Neurosciences Inc | $4.18 | — | — | — | -1888.70% | $5.51M |
| CDIOCardio Diagnostics Holdings, Inc. | $1.85 | — | 0.7x | — | -75.44% | $5.48M |
| PULMPulmatrix, Inc. | $1.51 | — | 3.5x | — | -98.35% | $5.51M |
| PMCBPharmaCyte Biotech, Inc. | $0.52 |
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Company description provided by Yahoo Finance.
| — |
| 0.2x |
| — |
| -44.72% |
| $5.53M |
| NCNANuCana plc | $1.33 | 0.0x | 0.2x | — | -70.26% | $5.54M |
| LABTLakewood-Amedex Biotherapeutics Inc. | $2.30 | — | 1.2x | — | -402.83% | $5.45M |